甘李药业：甘精胰岛素注射液获欧盟委员会上市批准

Core Viewpoint - Gan Li Pharmaceutical has received approval from the European Commission for its insulin injection product, marking its entry into the European market [1] Group 1: Product Approval - Gan Li Pharmaceutical's insulin injection, named Ondibta in the EU and Changxiulin in China, is approved for the treatment of diabetes in adults, adolescents, and children aged 2 years and older [1] - The product will be marketed in the European Union, Iceland, Liechtenstein, and Norway [1]